RecruitingPhase 1NCT06218784
A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
Studying NON RARE IN EUROPE: Post-herpetic neuralgia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- iN Therapeutics Co., Ltd.
- Intervention
- iN1011-N17 HCl Suspension (Part 1)(drug)
- Enrollment
- 64 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- CMAX Clinical Research, Adelaide, South Australia, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06218784 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Post-herpetic neuralgia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06420778The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With ElectroacupunctureZhejiang Chinese Medical University
- ENROLLING BY INVITATIONNCT06410222Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation.Feng Gao
- RECRUITINGNCT06942806The Efficacy of High-frequency Short-time Spinal Cord Stimulation in the Treatment of Herpes Zoster-associated NeuralgiaLi Zhao
- RECRUITINGNANCT06290661Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT04144972Closed-Loop Deep Brain Stimulation for Refractory Chronic PainUniversity of California, San Francisco
See all trials for NON RARE IN EUROPE: Post-herpetic neuralgia →